Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vikas Ostwal

Showing results (1-10 of 202) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
Reply to N. Okano et alAnant Ramaswamy, Vikas Ostwal
Nuclear Medicine Communications|April 23, 2016
Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?Sandip Basu, Vikas Ostwal
Translational Gastroenterology and Hepatology|December 22, 2017
What drives the wheel towards long-term outcome in advanced GIST, its size, genotype or may be a pill or two of imatinib?Vikas Ostwal, Anant Ramaswamy
International Journal of Rheumatic Diseases|April 9, 2010
Type B insulin resistance in a systemic lupus erythematosus patientVikas Ostwal, Jyotsna Oak
European Journal of Nuclear Medicine and Molecular Imaging|August 21, 2016
The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenariosSandip Basu, Vikas Ostwal
Journal of Gastrointestinal Cancer|January 21, 2020
Real-World Long-Term Outcomes with Perioperative EOX in D2 Gastrectomy: a Meaningful Look While We Switch to FLOT-4Anant Ramaswamy, Prabhat Bhargava, Vikas Ostwal
Journal of Gastrointestinal Oncology|June 11, 2016
Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experienceArvind Sahu, Anant Ramaswamy, Vikas Ostwal
Chinese Clinical Oncology|April 5, 2019
A step ahead on CTHRC1, and not just reinventing the wheel!Siddharth Turkar, Anant Ramaswamy, Vikas Ostwal
The National Medical Journal of India|June 12, 2012
Metastatic pancreatic cancer: another option?Shailesh V Shrikhande, Sudeep Gupta, Vikas Ostwal
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 13, 2014
Supportive measures and finer practice points in 177Lu-DOTATATE PRRT for NET: aiming for optimal disease managementSandip Basu, Vikas Ostwal, Rohit Ranade, et al.
Pageof 21

Showing results (1-10 of 202) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
Reply to N. Okano et alAnant Ramaswamy, Vikas Ostwal
Nuclear Medicine Communications|April 23, 2016
Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?Sandip Basu, Vikas Ostwal
Translational Gastroenterology and Hepatology|December 22, 2017
What drives the wheel towards long-term outcome in advanced GIST, its size, genotype or may be a pill or two of imatinib?Vikas Ostwal, Anant Ramaswamy
International Journal of Rheumatic Diseases|April 9, 2010
Type B insulin resistance in a systemic lupus erythematosus patientVikas Ostwal, Jyotsna Oak
European Journal of Nuclear Medicine and Molecular Imaging|August 21, 2016
The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenariosSandip Basu, Vikas Ostwal
Journal of Gastrointestinal Cancer|January 21, 2020
Real-World Long-Term Outcomes with Perioperative EOX in D2 Gastrectomy: a Meaningful Look While We Switch to FLOT-4Anant Ramaswamy, Prabhat Bhargava, Vikas Ostwal
Journal of Gastrointestinal Oncology|June 11, 2016
Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experienceArvind Sahu, Anant Ramaswamy, Vikas Ostwal
Chinese Clinical Oncology|April 5, 2019
A step ahead on CTHRC1, and not just reinventing the wheel!Siddharth Turkar, Anant Ramaswamy, Vikas Ostwal
The National Medical Journal of India|June 12, 2012
Metastatic pancreatic cancer: another option?Shailesh V Shrikhande, Sudeep Gupta, Vikas Ostwal
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 13, 2014
Supportive measures and finer practice points in 177Lu-DOTATATE PRRT for NET: aiming for optimal disease managementSandip Basu, Vikas Ostwal, Rohit Ranade, et al.
Pageof 21